Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 3/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 2/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7854181 | 0.98 | CCR3 (0.71) | CCR3ACHESIGMAR1ALDH1A1CXCR4 | |
| SCHEMBL5969122 | 0.89 | CCR3 (0.64) | CCR3ACHESIGMAR1ALDH1A1CXCR4 | |
| SCHEMBL5969123 | 0.89 | CCR3 (0.64) | CCR3ACHESIGMAR1ALDH1A1CXCR4 | |
| SCHEMBL1714316 | 0.85 | CCR3 (0.74) | CCR3ACHESIGMAR1ALDH1A1CXCR4 | |
| SCHEMBL2004615 | 0.85 | CCR3 (1.00) | CCR3ACHESIGMAR1ALDH1A1ATM | |
| SCHEMBL15140944 | 0.85 | CCR3 (0.73) | CCR3ACHESIGMAR1ALDH1A1CXCR4 | |
| Hydrochloric Acid SCHEMBL8342035 | 0.84 | CCR3 (0.72) | CCR3ACHEALDH1A1CXCR4ATM | |
| SCHEMBL27503860 | 0.84 | CCR3 (0.73) | CCR3ACHESIGMAR1 | |
| SCHEMBL3107807 | 0.83 | CCR3 (0.71) | CCR3ACHESIGMAR1ALDH1A1CXCR4 | |
| SCHEMBL7977320 | 0.83 | CCR3 (0.96) | CCR3ACHESIGMAR1ALDH1A1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999994-B2 | Derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-04-07 | — | — | US | disclosed |
| US-8999994-B2 | Derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-04-07 | — | — | US | disclosed |
| US-8999994-B2 | Derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-04-07 | — | — | US | disclosed |
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130012522-A1 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2013-01-10 | — | — | US | disclosed |
| US-20130012522-A1 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2013-01-10 | — | — | US | disclosed |
| US-20130012522-A1 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2013-01-10 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008073452-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073452-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-0881215-A1 | PROCESS FOR THE PREPARATION OF 4-METHYLENEPIPERIDINES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1998-12-02 | — | — | EP | disclosed |
| CN-1038839-C | Process for preparation of cyclic amine compounds | EISAI CO LTD (JP) | 1998-06-24 | — | — | CN | disclosed |
| US-5607950-A | IRRITABLE BOWEL SYNDROME | PFIZER INC. (US) | 1997-03-04 | — | — | US | disclosed |
| CN-1034015-C | Process to prepare cycloamine compounds | EISAI CO LTD (JP) | 1997-02-12 | — | — | CN | disclosed |
| EP-0508988-B1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 1994-03-02 | — | — | EP | disclosed |
| EP-0508988-A1 | MUSCARINIC RECEPTOR ANTAGONISTS. | PFIZER LTD (GB) | 1992-10-21 | — | — | EP | disclosed |
| WO-1991010647-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | ACHE, BCHE, CHKA | CCR3 4236/4885ACHE 1/4885SIGMAR1 4125/4885 |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHKA | CCR3 4236/4885ACHE 1/4885SIGMAR1 4125/4885 |
| US-20130012522-A1 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | CHRNA4, CHRNB4, CHRNA5 | CCR3 249/4885ACHE 88/4885SIGMAR1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.